News

Ruikang units to back $12M in new credit as revenue, profit slide

What's the deal? Ruikang Pharmaceutical Group said two wholly owned subsidiaries will provide joint liability guarantees for up to US$11.7M in new comprehensive credit facilities for the listed parent. The subsidiaries — Ruikang Pharmaceutical (Shandong) and Zibo Ruikang Drug Distribution — are backing the financing from domestic and overseas financial institutions.

Why now? The guarantees fall under a broader plan, approved by Ruikang's board on October 26, 2026, to seek total comprehensive credit lines of up to US$687.5M. Because the subsidiaries are wholly owned, the move cleared internal approvals and did not require a board or shareholder vote.

What's the context? Ruikang, a Yantai-based pharmaceutical and medical device distributor founded in 2004, is tapping credit as its core business weakens. Revenue fell 4.9% year on year in the first three quarters of 2026, while net profit attributable to the parent dropped 23.7%.

Operating cash flow fell 77.5% year on year over the same period, and the company posted a non-recurring net loss of US$2.32M.

By the numbers: As of the announcement, Ruikang's actual guarantee balance stood at US$57.2M, or 7.86% of its most recently audited net assets attributable to the parent. The company said it has no overdue guarantees, no guarantees involved in litigation, and is not a dishonest debtor subject to enforcement.

What the company says: Ruikang said the guarantees carry controllable risk and will help "enhance the listed company's financing capacity" and meet normal working capital needs. It added the arrangement does not harm the interests of shareholders, "especially small and medium shareholders."

The signal: This is routine financing support rather than a major capital transaction. But with profit and cash flow under pressure, Ruikang's access to credit and liquidity is worth tracking.

Read more: sohu.com

Image credit: Generated with Gemini

More top stories